---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-05-10T18:09:27.004897'
end_time: '2026-05-10T18:22:25.817099'
duration_seconds: 778.81
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: AARSD1
  gene_symbol: AARSD1
  uniprot_accession: Q9BTE6
  protein_description: 'RecName: Full=Alanyl-tRNA editing protein Aarsd1; AltName:
    Full=Alanyl-tRNA synthetase domain-containing protein 1;'
  gene_info: Name=AARSD1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the class-II aminoacyl-tRNA synthetase family.
  protein_domains: Ala-tRNA-synth_IIc_core. (IPR018165); Alanyl-tRNA_Editing_Enzymes.
    (IPR051335); Thr/Ala-tRNA-synth_IIc_edit. (IPR018163); Transl_B-barrel_sf. (IPR009000);
    tRNA_SAD. (IPR012947)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 18
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BTE6
- **Protein Description:** RecName: Full=Alanyl-tRNA editing protein Aarsd1; AltName: Full=Alanyl-tRNA synthetase domain-containing protein 1;
- **Gene Information:** Name=AARSD1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the class-II aminoacyl-tRNA synthetase family.
- **Key Domains:** Ala-tRNA-synth_IIc_core. (IPR018165); Alanyl-tRNA_Editing_Enzymes. (IPR051335); Thr/Ala-tRNA-synth_IIc_edit. (IPR018163); Transl_B-barrel_sf. (IPR009000); tRNA_SAD. (IPR012947)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AARSD1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AARSD1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AARSD1** (gene ID: AARSD1, UniProt: Q9BTE6) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BTE6
- **Protein Description:** RecName: Full=Alanyl-tRNA editing protein Aarsd1; AltName: Full=Alanyl-tRNA synthetase domain-containing protein 1;
- **Gene Information:** Name=AARSD1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the class-II aminoacyl-tRNA synthetase family.
- **Key Domains:** Ala-tRNA-synth_IIc_core. (IPR018165); Alanyl-tRNA_Editing_Enzymes. (IPR051335); Thr/Ala-tRNA-synth_IIc_edit. (IPR018163); Transl_B-barrel_sf. (IPR009000); tRNA_SAD. (IPR012947)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AARSD1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AARSD1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AARSD1** (gene ID: AARSD1, UniProt: Q9BTE6) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Research report: Human **AARSD1** (UniProt **Q9BTE6**) — functional annotation and current evidence

### 0) Identity verification (critical disambiguation)
The literature reviewed here matches the UniProt target provided (Q9BTE6) and refers to the human gene **AARSD1** encoding **human AlaX (hAlaX)** / **AlaXp**, a free-standing aminoacyl‑tRNA synthetase–related **editing** (proofreading) factor rather than a canonical aminoacyl‑tRNA synthetase. Li & Zhou (2024) explicitly identify “human AlaX (hAlaX) encoded by alanyl‑tRNA synthetase domain containing 1 (AARSD1)” and reference the AlphaFold model identifier **AF‑Q9BTE6‑F1**, linking the functional work directly to UniProt Q9BTE6. (li2024eukaryoticalaxprovides pages 1-2)

A key additional point for correct interpretation is that mammalian **AARSD1/Aarsd1** is alternatively spliced, producing isoforms that can include (i) a standalone AlaX/AlaXp editing region and (ii) a longer “fusion” isoform bearing an N‑terminal p23-like cochaperone (CS) domain fused to the AlaXp region, which is important for muscle biology (below). (echeverria2016aremodeledhsp90 pages 1-2, echeverria2016aremodeledhsp90 pages 2-3, echeverria2016aremodeledhsp90 media 711d0330)

### 1) Key concepts and definitions (current understanding)

#### 1.1 Aminoacyl‑tRNA editing and trans‑editing
Accurate translation requires correct pairing between amino acids and their cognate tRNAs (aa‑tRNAs). Aminoacyl‑tRNA synthetases (aaRSs) can make selection errors (e.g., activating serine instead of alanine). Many aaRSs therefore contain **editing domains** that hydrolyze incorrectly activated amino acids or mischarged aa‑tRNAs (“proofreading”). A distinct but related strategy is **trans‑editing**, where a **free-standing editing protein** (not fused to the aaRS) deacylates mischarged aa‑tRNAs.

**AARSD1/hAlaX** is such a free-standing, cytoplasmic **trans‑editing factor**: it hydrolyzes mischarged aa‑tRNAs (especially serine-mischarged tRNAs) to protect proteome fidelity and modulate decoding dynamics. (li2024eukaryoticalaxprovides pages 1-2, li2024eukaryoticalaxprovides pages 2-3)

#### 1.2 What “AlaX/AlaXp” means in mammals
“AlaX/AlaXp” refers to proteins homologous to the **editing domain of alanyl‑tRNA synthetase (AlaRS)** that can act independently as deacylases. A review on AlaRS biology summarizes that AlaXp proteins are free-standing homologs of the AlaRS editing domain, and (in vitro) can hydrolyze **Ser‑tRNAAla** and **Gly‑tRNAAla**. (zhang2021theuniquenessof pages 10-14)

### 2) Primary molecular function of human AARSD1: enzyme activity, reaction, and substrate specificity

#### 2.1 Reaction catalyzed
The best-supported primary biochemical function of human AARSD1 is **deacylation (hydrolysis) of misacylated aa‑tRNAs**, i.e., cleavage of the ester bond linking the amino acid to the 3′ end of tRNA, thereby converting aa‑tRNA back to uncharged tRNA and free amino acid. Li & Zhou (2024) describe human AlaX as an “active trans‑editing factor” with **strict serine specificity**, consistent with deacylation of serine-mischarged aa‑tRNAs. (li2024eukaryoticalaxprovides pages 1-2)

#### 2.2 Substrate specificity (which aa‑tRNAs are targeted)
**2024 mechanistic work (highest priority, primary research):**
* Human AARSD1 (hAlaX) is described as “predominantly hydrolyz[ing] Ser‑tRNAAla” and functioning as a “third sieve” of AlaRS. (li2024eukaryoticalaxprovides pages 1-2)
* The authors report that, in vitro, human and yeast AlaX “were capable of hydrolyzing nearly all Ser‑mischarged cytoplasmic and mitochondrial tRNAs,” and that explicitly tested substrates included **Ser‑tRNAAla**, **Ser‑tRNAThr**, **Ser‑tRNASer**, and **Ser‑tRNASec**. (li2024eukaryoticalaxprovides pages 1-2)
* The same work proposes broader roles: clearing **Ser‑tRNAAla** and **Ser‑tRNAThr** (proofreading “hubs” for AlaRS and ThrRS), and also tuning **Ser‑tRNASer** levels to influence serine decoding. (li2024eukaryoticalaxprovides pages 14-15, li2024eukaryoticalaxprovides pages 2-3)

**Background and family-level corroboration:**
A review of AlaRS uniqueness notes that AlaXp proteins (the family to which AARSD1 belongs) can hydrolyze **Ser‑tRNAAla** and **Gly‑tRNAAla** in vitro, and can rescue phenotypes of editing-defective AlaRS in bacterial models, supporting physiological relevance of this trans-editing activity as a general principle. (zhang2021theuniquenessof pages 10-14)

#### 2.3 Evidence for impact on translation fidelity in cells (functional outcomes)
Li & Zhou (2024) report that **loss** of yeast AlaX or human AlaX “readily induced Ala‑ and Thr‑to‑Ser misincorporation” (measured by LC–MS/MS), linking AARSD1 activity to **proteome-level amino acid substitutions** (a direct readout of translational infidelity). (li2024eukaryoticalaxprovides pages 1-2, li2024eukaryoticalaxprovides pages 14-15)

They further report that **overexpression** of editing-competent hAlaX impairs decoding efficiency of **consecutive serine codons**, consistent with a regulatory role that becomes apparent when AARSD1 levels are elevated. (li2024eukaryoticalaxprovides pages 1-2, li2024eukaryoticalaxprovides pages 15-16)

### 3) Protein features, domains, isoforms, and mechanistic implications

#### 3.1 Domain architecture relevant to function
Li & Zhou (2024) describe AARSD1/hAlaX as containing an **editing domain (ED)** and a **C‑Ala domain**, connected by **long helices** that also mediate **dimerization**; they also highlight conserved motifs (including **HXXXH** and **CXXXH**) forming a zinc‑finger–related motif important for editing. (li2024eukaryoticalaxprovides pages 5-7, li2024eukaryoticalaxprovides pages 7-8)

#### 3.2 Dimerization and interactions
Li & Zhou (2024) report that hAlaX forms **homodimers in vivo**, with dimerization mediated by hydrophobic/leucine-zipper interactions in the long connecting helices. They also report **no detectable interaction between hAlaX and cytoplasmic AlaRS** by co-immunoprecipitation, supporting a primarily **independent trans‑editing** role rather than stable complex formation with AlaRS. (li2024eukaryoticalaxprovides pages 5-7)

#### 3.3 Alternative splicing creates functionally distinct AARSD1 isoforms (translation editing vs chaperone biology)
A major complexity in functional annotation is that the mammalian locus produces isoforms with different domain combinations:
* Echeverría et al. (2016) describe isoforms that contain only the AlaXp editing region and longer isoforms combining an N‑terminal **p23-like CS domain** with AlaXp (a “fusion” protein). The CS domain can **inhibit AlaXp editing activity in cis or trans**, implying regulation of editing activity by isoform choice and/or protein-protein interactions. (echeverria2016aremodeledhsp90 pages 1-2)
* The domain schematic supporting this architecture (AlaRS vs AlaXp types and Aarsd1L fusion) is shown in a figure panel from Echeverría et al. (2016). (echeverria2016aremodeledhsp90 media 711d0330)

### 4) Subcellular localization and where AARSD1 acts
The strongest direct localization evidence comes from Li & Zhou (2024), who report that human AARSD1/hAlaX is **exclusively distributed in the cytoplasm**, with multiple orthogonal assays supporting lack of nuclear/mitochondrial localization:
* imaging of tagged constructs and antibody-based detection showed predominant cytoplasmic signal;
* nuclear/cytoplasmic fractionation with Western blotting showed absence from the nuclear fraction;
* mitochondrial fractionation and Western blotting showed no detectable mitochondrial localization. (li2024eukaryoticalaxprovides pages 5-7)

This cytoplasmic localization is also consistent with its role in editing cytoplasmic aa‑tRNA pools and with the 2016 observation that a muscle-relevant isoform participates in the cytosolic Hsp90 client machinery (e.g., glucocorticoid receptor). (li2024eukaryoticalaxprovides pages 5-7, echeverria2016aremodeledhsp90 pages 1-2)

### 5) Pathways and biological processes

#### 5.1 Translation quality control and decoding regulation
AARSD1/hAlaX is positioned in a **translation quality-control** pathway that prevents (or reduces) amino acid misincorporation by destroying mischarged aa‑tRNAs before ribosomal decoding. The 2024 work frames AlaX as providing “multiple checkpoints for quality and quantity of aminoacyl‑tRNAs” and proposes roles spanning proofreading for AlaRS/ThrRS and tuning serine decoding through effects on Ser‑tRNASer availability. (li2024eukaryoticalaxprovides pages 14-15, li2024eukaryoticalaxprovides pages 1-2, li2024eukaryoticalaxprovides pages 15-16)

#### 5.2 Connection to proteostasis via Hsp90 cochaperone remodeling in muscle
Echeverría et al. (2016) describe Aarsd1 as a **novel Hsp90 cochaperone** required for muscle differentiation, with a “cochaperone switch” where a muscle-specific Aarsd1 isoform replaces p23 in the Hsp90 ensemble during differentiation. This is a distinct functional context from tRNA editing but is mechanistically linked by alternative splicing and the presence of the p23-like CS domain in certain Aarsd1 isoforms. (echeverria2016aremodeledhsp90 pages 1-2, echeverria2016aremodeledhsp90 pages 3-4)

### 6) Recent developments (prioritizing 2023–2024)
The most substantial recent advance is the dedicated mechanistic characterization of **human AARSD1/AlaX** in 2024:
* Demonstration that hAlaX is a cytoplasmic, active trans‑editing factor with **strict Ser specificity**, with evidence spanning in vitro deacylation assays and cell-based phenotypes (misincorporation, codon decoding effects, and serine-stress growth effects). Publication date: **June 2024**. DOI/URL: **10.1093/nar/gkae486** / https://doi.org/10.1093/nar/gkae486. (li2024eukaryoticalaxprovides pages 1-2, li2024eukaryoticalaxprovides pages 5-7)
* Structural/organizational insights: ED + C‑Ala domains connected by long helices, homodimerization, and conserved motifs implicated in zinc coordination and editing activity. (li2024eukaryoticalaxprovides pages 5-7, li2024eukaryoticalaxprovides pages 7-8)

A 2024 review on the role of tRNA identity elements in aminoacyl‑tRNA editing contextualizes how editing domains (including free-standing editors) achieve selective hydrolysis while avoiding cognate aa‑tRNA destruction, providing conceptual support for interpreting AlaX/AARSD1 editing specificity, even though it is not specific to AARSD1. Publication date: **July 2024**. DOI/URL: **10.3389/fmicb.2024.1437528** / https://doi.org/10.3389/fmicb.2024.1437528. (li2024eukaryoticalaxprovides pages 7-8)

### 7) Current applications and real-world implementations

#### 7.1 Practical use as a translation-fidelity perturbation node (experimental biology)
Because AARSD1 directly controls the abundance of mischarged aa‑tRNAs, it is a practical lever in experimental systems to:
* induce or suppress specific **amino acid misincorporation** patterns (Ala/Thr→Ser) and assess proteotoxic outcomes (LC–MS/MS-based proteome readouts);
* modulate decoding of **poly‑Ser** segments using reporter systems (dual luciferase mentioned) to study codon-run translation dynamics. (li2024eukaryoticalaxprovides pages 1-2, li2024eukaryoticalaxprovides pages 14-15)

#### 7.2 Muscle biology and glucocorticoid signaling (proteostasis application)
In differentiated muscle models, Aarsd1L behaves as an Hsp90 cochaperone influencing glucocorticoid receptor behavior (a clinically relevant pathway in muscle wasting contexts). Echeverría et al. (2016) report that Aarsd1L overexpression slowed GR nuclear localization and repressed GR-dependent transcription, affecting Dex-induced expression of GR targets (e.g., Klf15, Fkbp5) and modulating Dex-driven myotube loss. Publication date: **April 2016**. DOI/URL: **10.1128/MCB.01099-15** / https://doi.org/10.1128/MCB.01099-15. (echeverria2016aremodeledhsp90 pages 6-7)

### 8) Expert opinions / authoritative synthesis
* A review focused on AlaRS biology emphasizes that standalone AlaRS editing-domain homologs (AlaXp) are broadly distributed and can hydrolyze mischarged Ser‑tRNAAla (and Gly‑tRNAAla in vitro), supporting the interpretation that AARSD1’s main role is translational proofreading rather than aminoacylation. (zhang2021theuniquenessof pages 10-14)
* The 2024 primary study extends this by arguing for “multiple checkpoints” and suggesting a regulatory role in serine decoding when AlaX levels are elevated (a potential non-canonical layer beyond strict error correction). (li2024eukaryoticalaxprovides pages 14-15, li2024eukaryoticalaxprovides pages 15-16)

### 9) Relevant statistics and quantitative data (from available evidence)

#### 9.1 Translation fidelity / editing load estimates
Li & Zhou (2024) provide two quantitative contextual estimates:
* escaped Ser‑mischarged tRNAAla or tRNAThr is estimated to be “**less than 0.1–1%**” of the respective pools (based on a discriminator factor deduction);
* catalytic efficiency for noncognate amino acids is “generally **2–3 orders of magnitude lower**” than for cognate amino acids. (li2024eukaryoticalaxprovides pages 15-16)

They also report a phenotype under amino acid stress: addition of **10 mM or 40 mM serine** markedly reduced growth of hAlaX knockout lines but not wild-type in the excerpted text. (li2024eukaryoticalaxprovides pages 14-15)

**Limitation:** Many numeric effect sizes (e.g., fold-change in luciferase, exact misincorporation percentages) are referenced as figure results in the paper but were not present as explicit numbers in the text excerpts available here. (li2024eukaryoticalaxprovides pages 14-15)

#### 9.2 Muscle differentiation / proteomics statistics (2016)
Echeverría et al. (2016) report proteomics-based summary statistics using a 1.2-fold cutoff: during differentiation, **761 proteins were upregulated and 871 downregulated**, and geldanamycin treatment altered **353 and 329 proteins** respectively. They also report that continuous geldanamycin at **10 nM** “completely abolished” myotube formation. (echeverria2016aremodeledhsp90 pages 7-8)

In GR nuclear localization assays, Aarsd1L effects were quantified across **three independent experiments** scoring **100 cells per time point**, with differences reaching **P ≤ 0.005** in the excerpted description. (echeverria2016aremodeledhsp90 pages 6-7)

### 10) Disease associations and biomedical relevance (current state)

#### 10.1 Curated target–disease evidence (Open Targets)
Open Targets reports disease associations for **AARSD1** (and also a PTGES3L‑AARSD1 readthrough) including **neurodegenerative disease** (reported score ~0.37) and oral squamous cell carcinoma, with evidence largely from CRISPR-screen datasets linked to PMID **34031600** (“Glutamatergic Neuron-Liperfluo-CRISPRi”). These associations should be interpreted as **hypothesis-generating** functional-genomics links rather than established Mendelian disease causality in the excerpts available here. (OpenTargets Search: -AARSD1)

**Limitation:** Within the retrieved evidence set, there was no direct report of a human Mendelian disorder caused by AARSD1 variants, and Open Targets evidence shown did not provide specific causal variants. (OpenTargets Search: -AARSD1)

### 11) Consolidated evidence table
The following table summarizes the key verified features of human AARSD1/Q9BTE6.

| Human gene / protein | Aliases used in literature | Main molecular function | Key substrates / scope | Key domains / structural features | Subcellular localization | Key evidence sources (year; DOI; URL) | Evidence IDs |
|---|---|---|---|---|---|---|---|
| **AARSD1** / **UniProt Q9BTE6** | Alanyl-tRNA editing protein Aarsd1; alanyl-tRNA synthetase domain-containing protein 1; **human AlaX (hAlaX)**; **AlaXp/AlaXP-type** trans-editing factor | Standalone **trans-editing / proofreading deacylase** that hydrolyzes **Ser-mischarged aa-tRNAs** to maintain translational fidelity; described as a “third sieve” for AlaRS and also impacting ThrRS/Ser codon decoding | Strongest evidence for **Ser-tRNA^Ala**; also edits **Ser-tRNA^Thr**, **Ser-tRNA^Ser**, and **Ser-tRNA^Sec**; 2024 work reports hydrolysis of **nearly all Ser-mischarged cytoplasmic and mitochondrial tRNAs** with an exception noted for **Ser-mt tRNA^Ala**; in vivo loss causes **Ala→Ser** and **Thr→Ser** misincorporation | Contains **editing (ED) domain** homologous to AlaRS/ThrRS editing domains plus **C-Ala tRNA-binding domain**; domains linked by **long helices** mediating **homodimerization**; active site includes conserved **HXXXH/CXXXH zinc-finger-related motifs**; C-Ala contains **Gly-rich** sequence implicated in tRNA interaction | **Cytoplasm**; experimentally **absent from nucleus and mitochondria** by imaging and fractionation/Western blot; no detectable interaction with cytoplasmic AlaRS in the 2024 study | Li & Zhou, **2024**; **10.1093/nar/gkae486**; https://doi.org/10.1093/nar/gkae486 ; Echeverría et al., **2016**; **10.1128/MCB.01099-15**; https://doi.org/10.1128/MCB.01099-15 ; Zhang et al., **2021**; **10.1080/15476286.2020.1861803**; https://doi.org/10.1080/15476286.2020.1861803 | (li2024eukaryoticalaxprovides pages 5-7, li2024eukaryoticalaxprovides pages 14-15, li2024eukaryoticalaxprovides pages 1-2, li2024eukaryoticalaxprovides pages 7-8, echeverria2016aremodeledhsp90 pages 1-2, echeverria2016aremodeledhsp90 pages 2-3, li2024eukaryoticalaxprovides pages 2-3, zhang2021theuniquenessof pages 10-14, echeverria2016aremodeledhsp90 media 711d0330) |


*Table: This table compacts the main verified annotations for human AARSD1/Q9BTE6, including its accepted aliases, trans-editing function, substrate scope, structural features, and localization. It is useful as a quick-reference evidence map before the full narrative report.*

### 12) Key figure supporting isoform/domain architecture
A domain schematic showing the relationship between AlaRS domains, AlaXp types, and the Aarsd1L fusion protein (including the p23-like CS domain) is provided in Echeverría et al. (2016). (echeverria2016aremodeledhsp90 media 711d0330)

### References (URLs and publication dates from evidence)
* Li Z-H, Zhou X-L. **Eukaryotic AlaX provides multiple checkpoints for quality and quantity of aminoacyl‑tRNAs in translation.** *Nucleic Acids Research.* **June 2024**. DOI: 10.1093/nar/gkae486. URL: https://doi.org/10.1093/nar/gkae486. (li2024eukaryoticalaxprovides pages 1-2)
* Echeverría PC, Briand P-A, Picard D. **A remodeled Hsp90 molecular chaperone ensemble with the novel cochaperone Aarsd1 is required for muscle differentiation.** *Molecular and Cellular Biology.* **April 2016**. DOI: 10.1128/MCB.01099-15. URL: https://doi.org/10.1128/MCB.01099-15. (echeverria2016aremodeledhsp90 pages 1-2)
* Zhang H, Yang X-L, Sun L. **The uniqueness of AlaRS and its human disease connections.** *RNA Biology.* **December 2021**. DOI: 10.1080/15476286.2020.1861803. URL: https://doi.org/10.1080/15476286.2020.1861803. (zhang2021theuniquenessof pages 10-14)
* Open Targets Platform disease associations for AARSD1 (accessed via tool context; platform paper cited in record: Buniello A et al., *Nucleic Acids Research*, 2025). (OpenTargets Search: -AARSD1)


References

1. (li2024eukaryoticalaxprovides pages 1-2): Zi-Han Li and Xiao-Long Zhou. Eukaryotic alax provides multiple checkpoints for quality and quantity of aminoacyl-trnas in translation. Nucleic Acids Research, 52:7825-7842, Jun 2024. URL: https://doi.org/10.1093/nar/gkae486, doi:10.1093/nar/gkae486. This article has 3 citations and is from a highest quality peer-reviewed journal.

2. (echeverria2016aremodeledhsp90 pages 1-2): Pablo C. Echeverría, Pierre-André Briand, and Didier Picard. A remodeled hsp90 molecular chaperone ensemble with the novel cochaperone aarsd1 is required for muscle differentiation. Molecular and Cellular Biology, 36:1310-1321, Apr 2016. URL: https://doi.org/10.1128/mcb.01099-15, doi:10.1128/mcb.01099-15. This article has 43 citations and is from a domain leading peer-reviewed journal.

3. (echeverria2016aremodeledhsp90 pages 2-3): Pablo C. Echeverría, Pierre-André Briand, and Didier Picard. A remodeled hsp90 molecular chaperone ensemble with the novel cochaperone aarsd1 is required for muscle differentiation. Molecular and Cellular Biology, 36:1310-1321, Apr 2016. URL: https://doi.org/10.1128/mcb.01099-15, doi:10.1128/mcb.01099-15. This article has 43 citations and is from a domain leading peer-reviewed journal.

4. (echeverria2016aremodeledhsp90 media 711d0330): Pablo C. Echeverría, Pierre-André Briand, and Didier Picard. A remodeled hsp90 molecular chaperone ensemble with the novel cochaperone aarsd1 is required for muscle differentiation. Molecular and Cellular Biology, 36:1310-1321, Apr 2016. URL: https://doi.org/10.1128/mcb.01099-15, doi:10.1128/mcb.01099-15. This article has 43 citations and is from a domain leading peer-reviewed journal.

5. (li2024eukaryoticalaxprovides pages 2-3): Zi-Han Li and Xiao-Long Zhou. Eukaryotic alax provides multiple checkpoints for quality and quantity of aminoacyl-trnas in translation. Nucleic Acids Research, 52:7825-7842, Jun 2024. URL: https://doi.org/10.1093/nar/gkae486, doi:10.1093/nar/gkae486. This article has 3 citations and is from a highest quality peer-reviewed journal.

6. (zhang2021theuniquenessof pages 10-14): Han Zhang, Xiang-Lei Yang, and Litao Sun. The uniqueness of alars and its human disease connections. RNA Biology, 18:1501-1511, Dec 2021. URL: https://doi.org/10.1080/15476286.2020.1861803, doi:10.1080/15476286.2020.1861803. This article has 13 citations and is from a peer-reviewed journal.

7. (li2024eukaryoticalaxprovides pages 14-15): Zi-Han Li and Xiao-Long Zhou. Eukaryotic alax provides multiple checkpoints for quality and quantity of aminoacyl-trnas in translation. Nucleic Acids Research, 52:7825-7842, Jun 2024. URL: https://doi.org/10.1093/nar/gkae486, doi:10.1093/nar/gkae486. This article has 3 citations and is from a highest quality peer-reviewed journal.

8. (li2024eukaryoticalaxprovides pages 15-16): Zi-Han Li and Xiao-Long Zhou. Eukaryotic alax provides multiple checkpoints for quality and quantity of aminoacyl-trnas in translation. Nucleic Acids Research, 52:7825-7842, Jun 2024. URL: https://doi.org/10.1093/nar/gkae486, doi:10.1093/nar/gkae486. This article has 3 citations and is from a highest quality peer-reviewed journal.

9. (li2024eukaryoticalaxprovides pages 5-7): Zi-Han Li and Xiao-Long Zhou. Eukaryotic alax provides multiple checkpoints for quality and quantity of aminoacyl-trnas in translation. Nucleic Acids Research, 52:7825-7842, Jun 2024. URL: https://doi.org/10.1093/nar/gkae486, doi:10.1093/nar/gkae486. This article has 3 citations and is from a highest quality peer-reviewed journal.

10. (li2024eukaryoticalaxprovides pages 7-8): Zi-Han Li and Xiao-Long Zhou. Eukaryotic alax provides multiple checkpoints for quality and quantity of aminoacyl-trnas in translation. Nucleic Acids Research, 52:7825-7842, Jun 2024. URL: https://doi.org/10.1093/nar/gkae486, doi:10.1093/nar/gkae486. This article has 3 citations and is from a highest quality peer-reviewed journal.

11. (echeverria2016aremodeledhsp90 pages 3-4): Pablo C. Echeverría, Pierre-André Briand, and Didier Picard. A remodeled hsp90 molecular chaperone ensemble with the novel cochaperone aarsd1 is required for muscle differentiation. Molecular and Cellular Biology, 36:1310-1321, Apr 2016. URL: https://doi.org/10.1128/mcb.01099-15, doi:10.1128/mcb.01099-15. This article has 43 citations and is from a domain leading peer-reviewed journal.

12. (echeverria2016aremodeledhsp90 pages 6-7): Pablo C. Echeverría, Pierre-André Briand, and Didier Picard. A remodeled hsp90 molecular chaperone ensemble with the novel cochaperone aarsd1 is required for muscle differentiation. Molecular and Cellular Biology, 36:1310-1321, Apr 2016. URL: https://doi.org/10.1128/mcb.01099-15, doi:10.1128/mcb.01099-15. This article has 43 citations and is from a domain leading peer-reviewed journal.

13. (echeverria2016aremodeledhsp90 pages 7-8): Pablo C. Echeverría, Pierre-André Briand, and Didier Picard. A remodeled hsp90 molecular chaperone ensemble with the novel cochaperone aarsd1 is required for muscle differentiation. Molecular and Cellular Biology, 36:1310-1321, Apr 2016. URL: https://doi.org/10.1128/mcb.01099-15, doi:10.1128/mcb.01099-15. This article has 43 citations and is from a domain leading peer-reviewed journal.

14. (OpenTargets Search: -AARSD1): Open Targets Query (-AARSD1, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

## Citations

1. li2024eukaryoticalaxprovides pages 1-2
2. zhang2021theuniquenessof pages 10-14
3. li2024eukaryoticalaxprovides pages 5-7
4. li2024eukaryoticalaxprovides pages 7-8
5. li2024eukaryoticalaxprovides pages 15-16
6. li2024eukaryoticalaxprovides pages 14-15
7. li2024eukaryoticalaxprovides pages 2-3
8. ing
9. https://doi.org/10.1093/nar/gkae486.
10. https://doi.org/10.3389/fmicb.2024.1437528.
11. https://doi.org/10.1128/MCB.01099-15.
12. https://doi.org/10.1093/nar/gkae486
13. https://doi.org/10.1128/MCB.01099-15
14. https://doi.org/10.1080/15476286.2020.1861803
15. https://doi.org/10.1080/15476286.2020.1861803.
16. https://doi.org/10.1093/nar/gkae486,
17. https://doi.org/10.1128/mcb.01099-15,
18. https://doi.org/10.1080/15476286.2020.1861803,